多潘立酮联合康复新液治疗反流性食管炎的疗效

Efficacy of domperidone combined with Kangfuxin Fluid in treating reflux esophagitis

  • 摘要: 目的 观察多潘立酮联合康复新液治疗反流性食管炎的疗效及对血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)水平的影响。 方法 将86例反流性食管炎患者按照随机数字表法分为实验组和对照组,每组43例。对照组采用单纯康复新液治疗,实验组采用多潘立酮联合康复新液口服治疗。比较2组临床疗效, CRP、IL-6、IL-10的变化以及治疗期间不良反应的发生情况。 结果 治疗8周后, 2组CRP、IL-6、IL-10水平低于治疗前,且实验组CRP、IL-6、IL-10水平低于对照组,差异有统计学意义(P<0.05)。实验组总有效率高于对照组,差异有统计学意义(P<0.05)。2组治疗期间腹泻、乏力、便秘等不良反应发生率比较,差异无统计学意义(P>0.05)。 结论 多潘立酮联合康复新液能有效缓解反流性食管炎的临床症状,降低血清CRP、IL-6、IL-10水平,减轻炎性反应。

     

    Abstract: Objective To observe effect of domperidone combined with Kangfuxin Fluid in treating reflux esophagitis and its effect on levels of C-reactive protein(CRP), interleukin-6(IL-6), and interleukin-10(IL-10). Methods A total of 86 patients with reflux esophagitis were divided into experimental group and control group according to random number table method, with 43 cases in each group. The control group was treated with Kangfuxin Fluid alone, while the experimental group was treated with domperidone combined with Kangfuxin Fluid. The clinical efficacy, changes of serum CRP, IL-6 and IL-10 and adverse reactions occurred during treatment were compared between the two groups. Results The CRP, IL-6 and IL-10 levels after 8 weeks of treatment in both groups were significantly lower than those before treatment, and were significantly lower in the experimental group than those of the control group(P<0.05). The total effective rate of the experimental group was significantly higher than that of the control group(P<0.05). During treatment, there were no significant differences in the incidence rates of diarrhea, fatigue, constipation and other adverse reactions(P>0.05). Conclusion Dopperidone combined with Kangfuxin Fluid can effectively relieve the clinical symptoms of reflux esophagitis, reduce the levels of serum CRP, IL-6 and IL-10, and alleviate the inflammatory reactions.

     

/

返回文章
返回